Travere Therapeutics (TVTX) Net Income towards Common Stockholders: 2011-2025
Historic Net Income towards Common Stockholders for Travere Therapeutics (TVTX) over the last 13 years, with Sep 2025 value amounting to $25.7 million.
- Travere Therapeutics' Net Income towards Common Stockholders rose 25806.00% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.3 million, marking a year-over-year decrease of 1014.35%. This contributed to the annual value of -$915,000 for FY2024, which is 100.35% down from last year.
- Latest data reveals that Travere Therapeutics reported Net Income towards Common Stockholders of $25.7 million as of Q3 2025, which was up 301.54% from -$12.8 million recorded in Q2 2025.
- Over the past 5 years, Travere Therapeutics' Net Income towards Common Stockholders peaked at $240.0 million during Q3 2023, and registered a low of -$88.8 million during Q4 2021.
- Over the past 3 years, Travere Therapeutics' median Net Income towards Common Stockholders value was -$100,000 (recorded in 2024), while the average stood at $21.4 million.
- Examining YoY changes over the last 5 years, Travere Therapeutics' Net Income towards Common Stockholders showed a top increase of 25,806.00% in 2025 and a maximum decrease of 39,925.24% in 2025.
- Travere Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$88.8 million in 2021, then soared by 122.32% to $19.8 million in 2022, then plummeted by 107.96% to -$1.6 million in 2023, then spiked by 100.25% to $4,000 in 2024, then spiked by 25,806.00% to $25.7 million in 2025.
- Its Net Income towards Common Stockholders stands at $25.7 million for Q3 2025, versus -$12.8 million for Q2 2025 and -$41.2 million for Q1 2025.